Compare UE & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UE | SLNO |
|---|---|---|
| Founded | 2014 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.3B |
| IPO Year | 2014 | 2014 |
| Metric | UE | SLNO |
|---|---|---|
| Price | $21.07 | $38.73 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | $22.00 | ★ $109.82 |
| AVG Volume (30 Days) | 937.3K | ★ 1.3M |
| Earning Date | 05-13-2026 | 05-29-2026 |
| Dividend Yield | ★ 4.01% | N/A |
| EPS Growth | 23.33 | ★ 108.90 |
| EPS | ★ 0.74 | 0.39 |
| Revenue | ★ $471,935,000.00 | $1,450,788.00 |
| Revenue This Year | N/A | $158.91 |
| Revenue Next Year | N/A | $54.20 |
| P/E Ratio | ★ $28.32 | $98.00 |
| Revenue Growth | 6.06 | ★ 138.82 |
| 52 Week Low | $15.66 | $32.63 |
| 52 Week High | $21.87 | $89.12 |
| Indicator | UE | SLNO |
|---|---|---|
| Relative Strength Index (RSI) | 59.68 | 44.22 |
| Support Level | $18.53 | $38.17 |
| Resistance Level | $21.68 | $44.60 |
| Average True Range (ATR) | 0.40 | 2.39 |
| MACD | -0.03 | 0.12 |
| Stochastic Oscillator | 50.71 | 65.01 |
Urban Edge Properties is a real estate investment trust principally focused on the management and development of retail real estate properties in urban communities in the U.S. Having originally been created to hold the majority of Vornado Realty Trust's shopping center businesses, Urban Edge's asset portfolio is mostly composed of shopping centers and malls in terms of total square footage. The company's holdings include necessity and convenience-oriented retailers, such as department stores, grocers, health clubs, and restaurants. Urban Edge's properties are mainly located in the New York City metropolitan region and within the DC to Boston corridor. The company generates nearly all of its revenue through the collection of rent from a large number of tenants.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.